Supernus Pharmaceuticals signed a definitive agreement to acquire fellow biopharmaceutical company Sage Therapeutics for $8.50 a share in a deal worth an initial $561 million.The terms of the deal also include one non-tradable contingent value right (CVR) payable upon achieving certain sales goals,

Supernus Pharmaceuticals will acquire Sage Therapeutics in a deal worth up to $795 million, gaining access to the only postpartum depression pill approved in the United States, the companies said on Monday.